Maravai Lifesciences Holdings (MRVI) Revenue (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Revenue of $65.8 million for Q1 2026, up 40.53% year-over-year from $46.8 million in Q1 2025, and up 32.03% quarter-over-quarter from $49.9 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Revenue (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Revenue history runs 7 years deep, the most recent figure standing at $65.8 million for Q1 2026.
- In Q1 2026, Revenue rose 40.53% year-over-year to $65.8 million; the TTM figure through Mar 2026 stood at $204.7 million (down 15.35% YoY), while the FY2025 annual figure was $185.7 million, down 28.34% from the prior year.
- Revenue for Q1 2026 stood at $65.8 million, up from $49.9 million in the prior quarter.
- The five-year high for Revenue was $244.3 million in Q1 2022, with the low at $41.6 million in Q3 2025.
- The 5-year median for Revenue is $68.9 million (2023), against an average of $99.0 million.
- The sharpest annual moves came in 2022 and 2023: Revenue soared 64.83% in 2022, then sank 71.61% in 2023.
- Maravai Lifesciences Holdings' Revenue stood at $204.7 million in 2022, then sank by 63.78% to $74.1 million in 2023, then retreated by 23.72% to $56.6 million in 2024, then fell by 11.83% to $49.9 million in 2025, then jumped by 32.03% to $65.8 million in 2026.
- Business Quant data shows MRVI's Revenue at $65.8 million in Q1 2026, $49.9 million in Q4 2025, and $41.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 51.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.44 Mn |
| Mar 31, 2026 | 65.84 Mn |
| Dec 31, 2025 | 49.87 Mn |
| Sep 30, 2025 | 41.63 Mn |
| Jun 30, 2025 | 47.40 Mn |
| Mar 31, 2025 | 46.85 Mn |
| Dec 31, 2024 | 56.56 Mn |
| Sep 30, 2024 | 69.03 Mn |
| Jun 30, 2024 | 69.42 Mn |
| Mar 31, 2024 | 64.18 Mn |
| Dec 31, 2023 | 74.14 Mn |
| Sep 30, 2023 | 66.87 Mn |
| Jun 30, 2023 | 68.91 Mn |
| Mar 31, 2023 | 79.03 Mn |
| Dec 31, 2022 | 204.71 Mn |
| Sep 30, 2022 | 191.26 Mn |
| Jun 30, 2022 | 242.73 Mn |
| Mar 31, 2022 | 244.29 Mn |
| Dec 31, 2021 | 228.44 Mn |
| Sep 30, 2021 | 204.81 Mn |